Emgality

Emgality (galcanezumab-gnlm) is a humanized injectable biologic manufactured by Eli Lilly and Company, FDA-approved in September 2018. It is used for the preventive treatment of migraine and is the only CGRP inhibitor approved for episodic cluster headache — a particularly severe and debilitating headache condition. Emgality blocks the CGRP ligand to prevent the neurogenic cascade underlying both conditions.

Emgality belongs to the CGRP inhibitor class, alongside Aimovig (erenumab, which blocks the CGRP receptor) and Ajovy (fremanezumab, which blocks the CGRP ligand). All three are monthly injectables for migraine prevention.

## What Emgality is used for

Emgality is FDA-approved for adults with: - Migraine prevention: reducing the frequency of migraine days - Episodic cluster headache: treating active cluster periods (the only CGRP inhibitor with this indication)

## Emgality loading dose

For migraine prevention, Emgality uses a loading dose strategy: - Loading dose (Month 1): 240 mg — given as two consecutive 120 mg injections at the same visit - Maintenance: 120 mg subcutaneously once monthly

The loading dose achieves rapid therapeutic blood levels, potentially providing benefit sooner than if starting with the maintenance dose alone.

For episodic cluster headache: - 300 mg (three 100 mg injections) at the start of a cluster period - Then 300 mg monthly for the duration of the cluster period

## Why does Emgality have a loading dose?

The loading dose rapidly saturates CGRP binding, achieving protective drug levels faster than starting with the maintenance dose. This can shorten the time to first benefit, which is important for patients dealing with frequent migraine attacks.

## How long does it take for Emgality to work?

Many patients see fewer migraine days within the first month (during and after the loading dose). In clinical trials (EVOLVE-1 and EVOLVE-2), Emgality reduced monthly migraine days by 4–5 days compared to placebo. Full response is typically evaluated after 3 months.

## Emgality vs. Aimovig — what's the difference?

• Emgality targets the CGRP ligand (the molecule itself)
• Aimovig targets the CGRP receptor (the binding site on cells)
• Emgality is also approved for cluster headache; Aimovig is not
• Emgality uses a loading dose regimen; Aimovig does not
• Emgality is made by Lilly; Aimovig is made by Amgen/Novartis

## Side effects of Emgality

Common (≥2%): injection-site reactions (pain, redness, swelling), constipation.

Serious: hypersensitivity reactions including anaphylaxis and angioedema (rare). Post-marketing reports include hair loss (alopecia) and Raynaud's phenomenon, though causal relationships have not been firmly established.

## Does Emgality cause weight gain?

Weight gain is not a recognized side effect of Emgality. It has minimal effect on systemic physiology outside the CGRP pathway. Any weight changes are more likely related to lifestyle improvements from better migraine control.

## Is Emgality an immunosuppressant?

No. Emgality does not suppress the immune system. It specifically blocks CGRP, a neuropeptide involved in pain signaling and vasodilation. Unlike DMARDs or anti-CD20 antibodies, Emgality does not affect B-cells, T-cells, or general immunity.

## Emgality cost and savings

Emgality list price is approximately $7,000–$8,000 per year. Lilly's Emgality savings card can significantly reduce costs: - Emgality $0 savings card: eligible commercially insured patients may pay $0 per month - Emgality savings card after 12 months: the savings program continues beyond 12 months for eligible patients, though terms may change — verify with Lilly at enrollment renewal - Patient assistance program: available for uninsured/underinsured patients who qualify

## Emgality pen vs. syringe

Emgality comes in two forms: - Autoinjector pen (120 mg): a push-to-inject device requiring no needle handling - Prefilled syringe (120 mg or 100 mg): for patients or providers who prefer manual control

Both deliver the same medication. The pen is generally preferred for self-administration due to ease of use.

## Storage: how long can Emgality be out of the fridge?

Emgality can be stored at room temperature (up to 30°C / 86°F) for up to 7 days. After removal from the refrigerator, bring to room temperature for 30 minutes before injecting to reduce injection discomfort. Once the 7-day window passes, discard.

## Medical disclaimer

This article about Emgality (galcanezumab) is for educational purposes only. Always consult your neurologist or headache specialist for personalized guidance.